Here are the 424B prospectus supplements from Mangoceuticals, Inc. (MGRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGRX filings page.
Mangoceuticals, Inc. (MGRX) is offering 657,000 common shares with 657,000 accompanying common warrants and separately registering up to 788,400 common shares issuable upon warrant exercise. The combined offering price is $0.75 per share and accompanying warrant; estimated net proceeds are approximately $475,000 after offering expenses, for working capital and general corporate purposes. There is no minimum offering amount as a condition to closing, and delivery is expected on or about October 9, 2026, subject to satisfaction of certain customary closing conditions.
The warrants are immediately exercisable at $1.00 per share and expire five years from issuance; holders may elect cashless exercise at 1.2 shares for each share underlying a warrant. A holder and its affiliates generally may not exceed 4.99% ownership after exercise, or 9.99% at the holder’s election. The warrants will not be listed, and Mangoceuticals does not expect an active trading market. The prospectus estimates immediate net tangible book value dilution of $0.78 per share for participating investors. The independent auditor’s report contains an explanatory paragraph regarding substantial doubt about the company’s ability to continue as a going concern.